Eli Lilly is acquiring clinical-stage Dice Therapeutics in a $2.4 billion deal that brings drug candidates in patient-friendly pill formulations that could become successors to infused or injected ...

Eli Lilly and Co will buy Dice Therapeutics Inc for about $2.4 billion in cash, the company said on Tuesday, bolstering its immune disease-related portfolio with an experimental pill to treat ...